KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biolife Solutions (BLFS) Capital Leases (2019 - 2024)

Biolife Solutions (BLFS) has disclosed Capital Leases for 6 consecutive years, with $913000.0 as the latest value for Q3 2024.

  • Quarterly Capital Leases fell 26.96% to $913000.0 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $913000.0 through Sep 2024, down 26.96% year-over-year, with the annual reading at $1.2 million for FY2023, 819.05% up from the prior year.
  • Capital Leases for Q3 2024 was $913000.0 at Biolife Solutions, down from $996000.0 in the prior quarter.
  • The five-year high for Capital Leases was $1.3 million in Q2 2023, with the low at $12000.0 in Q4 2020.
  • Average Capital Leases over 5 years is $556312.5, with a median of $322500.0 recorded in 2021.
  • The sharpest move saw Capital Leases skyrocketed 2325.0% in 2021, then plummeted 62.45% in 2023.
  • Over 5 years, Capital Leases stood at $12000.0 in 2020, then surged by 2325.0% to $291000.0 in 2021, then plummeted by 56.7% to $126000.0 in 2022, then skyrocketed by 819.05% to $1.2 million in 2023, then decreased by 21.16% to $913000.0 in 2024.
  • According to Business Quant data, Capital Leases over the past three periods came in at $913000.0, $996000.0, and $1.1 million for Q3 2024, Q2 2024, and Q1 2024 respectively.